董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Lisa Dalton | 女 | Director | 48 | 未披露 | 未持股 | 2021-06-01 |
| George H. Talbot | 男 | Director | 73 | 7.59万美元 | 未持股 | 2021-06-01 |
| Steven Gelone | 男 | Director, President and Chief Operating Officer | 53 | 115.45万美元 | 未持股 | 2021-06-01 |
| Mark Corrigan | 男 | Director | 63 | 2.11万美元 | 未持股 | 2021-06-01 |
| Daniel Burgess | 男 | Director, Chairman of the Board | 59 | 12.09万美元 | 未持股 | 2021-06-01 |
| Stephen Webster | 男 | Director | 60 | 9.59万美元 | 未持股 | 2021-06-01 |
| Carrie Bourdow | 女 | Director | 58 | 7.84万美元 | 未持股 | 2021-06-01 |
| Theodore Schroeder | 男 | Director, Chief Executive Officer | 66 | 165.46万美元 | 未持股 | 2021-06-01 |
| Charles A. Rowland, Jr. | 男 | Director | 62 | 9.59万美元 | 未持股 | 2021-06-01 |
| Colin Broom | 男 | Director | 65 | 7.09万美元 | 未持股 | 2021-06-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Steven Gelone | 男 | Director, President and Chief Operating Officer | 53 | 115.45万美元 | 未持股 | 2021-06-01 |
| Daniel Burgess | 男 | Director, Chairman of the Board | 59 | 12.09万美元 | 未持股 | 2021-06-01 |
| Robert Crotty | 男 | General Counsel and Secretary | 47 | 未披露 | 未持股 | 2021-06-01 |
| Theodore Schroeder | 男 | Director, Chief Executive Officer | 66 | 165.46万美元 | 未持股 | 2021-06-01 |
| Daniel Dolan | 男 | Chief Financial Officer | 44 | 未披露 | 未持股 | 2021-06-01 |
董事简历
中英对照 | 中文 | 英文- Lisa Dalton
-
Lisa Dalton从2014年7月开始担任我司人力资源部的主管。加入Spark前，Dalton女士担任Shire Pharmaceutical人力资源部的副总裁，她在该部门最后领导了人力资源业务的并购活动及实施。Dalton女士还担任过与富兰克林邓普顿投资公司（Franklin Templeton）和美国应用生物系统公司（Applied Biosystems）合作的薪酬及人力资源业务的多个职位。Dalton女士在美国宾州州立大学（Penn State University）获得心理学文学学士学位；在美国罗格斯大学（Rutgers University）商学院获得工商管理硕士学位。
Lisa Dalton has served on our board of directors since June 2 2021. Ms. Dalton has served as the chief people officer at Spark Therapeutics, a member of the Roche Group, since July 2014. She previously served as vice president, human resources at Shire. Ms. Dalton received her M.B.A. from Rutgers University School of Business and B.A. from Pennsylvania State University. - Lisa Dalton从2014年7月开始担任我司人力资源部的主管。加入Spark前，Dalton女士担任Shire Pharmaceutical人力资源部的副总裁，她在该部门最后领导了人力资源业务的并购活动及实施。Dalton女士还担任过与富兰克林邓普顿投资公司（Franklin Templeton）和美国应用生物系统公司（Applied Biosystems）合作的薪酬及人力资源业务的多个职位。Dalton女士在美国宾州州立大学（Penn State University）获得心理学文学学士学位；在美国罗格斯大学（Rutgers University）商学院获得工商管理硕士学位。
- Lisa Dalton has served on our board of directors since June 2 2021. Ms. Dalton has served as the chief people officer at Spark Therapeutics, a member of the Roche Group, since July 2014. She previously served as vice president, human resources at Shire. Ms. Dalton received her M.B.A. from Rutgers University School of Business and B.A. from Pennsylvania State University.
- George H. Talbot
-
George H. Talbot自2009年起在公司监事会工作。Talbot博士是Talbot Advisors 有限责任公司（Talbot Advisors LLC，一家生物制药公司顾问）负责人（2007年起）和在那之前（2000-2006年）。2006-2007年他担任Cerexa股份有限公司（Cerexa, Inc.）的首席医疗官和执行副总裁。他拥有卫斯理大学（Wesleyan University）学士学位，耶鲁大学医学院（Yale University School of Medicine）硕士学位和宾夕法尼亚大学（University of Pennsylvania）传染病课程培训。在担任宾夕法尼亚大学（University of Pennsylvania）传染病系的教员之后，他于1990年加入Rhone-Poulenc-Rorer的反传染集团。
George H. Talbot has served on our board of directors since June 23 2017. Dr. Talbot previously served on the supervisory board of Nabriva Austria from 2009 until the Redomiciliation. Dr. Talbot has been the principal at Talbot Advisors LLC, a biopharmaceutical company consultancy, since 2007 and prior to that, from 2000 to 2006. From 2006 to 2007 he served as chief medical officer and executive vice president of Cerexa, Inc. prior to its acquisition by Forest Laboratories, Inc. Dr. Talbot also worked closely with Calixa Therapeutics, Inc. and Durata Therapeutics, Inc., prior to their acquisitions by Cubist Pharmaceuticals, Inc. and Actavis plc, respectively. He was an initial member of the Infectious Diseases Society of America’s Antimicrobial Availability Task Force “Bad Bugs, No Drugs” and recently completed a seven-year tenure as co-chair of the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Projects for Endpoint Development in Acute Bacterial Skin and Skin Structure Infections, Community-acquired Bacterial Pneumonia, and Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial Pneumonia, which made evidence-based recommendations to the Food and Drug Administration for its Guidance development in these indications. Dr. Talbot received his B.A. from Wesleyan University, his M.D. from the Yale University School of Medicine, and his Infectious Diseases fellowship training at the University of Pennsylvania. After serving as a faculty member of the Infectious Diseases Section at the University of Pennsylvania, he joined the anti-infectives group at Rhone-Poulenc-Rorer in 1990. - George H. Talbot自2009年起在公司监事会工作。Talbot博士是Talbot Advisors 有限责任公司（Talbot Advisors LLC，一家生物制药公司顾问）负责人（2007年起）和在那之前（2000-2006年）。2006-2007年他担任Cerexa股份有限公司（Cerexa, Inc.）的首席医疗官和执行副总裁。他拥有卫斯理大学（Wesleyan University）学士学位，耶鲁大学医学院（Yale University School of Medicine）硕士学位和宾夕法尼亚大学（University of Pennsylvania）传染病课程培训。在担任宾夕法尼亚大学（University of Pennsylvania）传染病系的教员之后，他于1990年加入Rhone-Poulenc-Rorer的反传染集团。
- George H. Talbot has served on our board of directors since June 23 2017. Dr. Talbot previously served on the supervisory board of Nabriva Austria from 2009 until the Redomiciliation. Dr. Talbot has been the principal at Talbot Advisors LLC, a biopharmaceutical company consultancy, since 2007 and prior to that, from 2000 to 2006. From 2006 to 2007 he served as chief medical officer and executive vice president of Cerexa, Inc. prior to its acquisition by Forest Laboratories, Inc. Dr. Talbot also worked closely with Calixa Therapeutics, Inc. and Durata Therapeutics, Inc., prior to their acquisitions by Cubist Pharmaceuticals, Inc. and Actavis plc, respectively. He was an initial member of the Infectious Diseases Society of America’s Antimicrobial Availability Task Force “Bad Bugs, No Drugs” and recently completed a seven-year tenure as co-chair of the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Projects for Endpoint Development in Acute Bacterial Skin and Skin Structure Infections, Community-acquired Bacterial Pneumonia, and Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial Pneumonia, which made evidence-based recommendations to the Food and Drug Administration for its Guidance development in these indications. Dr. Talbot received his B.A. from Wesleyan University, his M.D. from the Yale University School of Medicine, and his Infectious Diseases fellowship training at the University of Pennsylvania. After serving as a faculty member of the Infectious Diseases Section at the University of Pennsylvania, he joined the anti-infectives group at Rhone-Poulenc-Rorer in 1990.
- Steven Gelone
-
Steven Gelone自2014年起担任公司的首席发展官。再加入公司之前，他在Spark Therapeutics股份有限公司（Spark Therapeutics, Inc.）担任临床研发负责人（2014年）和ViroPharma股份有限公司（ViroPharma, Inc.）临床和临床前开发副总裁（2005-2014年）。Gelone博士也在Vicuron Pharmaceuticals担任医疗事务董事（2002-2003年），也是GlaxoSmithKline Pharmaceuticals临床制药和经验型药物的董事（2000-2002年）。Gelone博士拥有天普大学（Temple University）药学学士学位和博士学位。
Steven Gelone has served on our board of directors since March 10 2021 and as our president and chief operating officer since July 24 2018. Dr. Gelone previously served as Nabriva Austria’s chief development officer and head of business development from 2014 until the Redomiciliation, our chief development officer from the Redomiciliation until June 30 2017 and our chief scientific officer from June 30 2017 until July 24 2018. Prior to joining Nabriva Austria, he served as head of clinical research and development at Spark Therapeutics, Inc. in 2014 and vice president of clinical and preclinical development at ViroPharma Incorporated from 2005 to 2014. Dr. Gelone also served as director of medical affairs at Vicuron Pharmaceuticals from 2002 to 2003 and director of clinical pharmacology and experimental medicine at GlaxoSmithKline Pharmaceuticals from 2000 to 2002. Dr. Gelone received his B.S. Pharm. and Pharm.D. from Temple University. - Steven Gelone自2014年起担任公司的首席发展官。再加入公司之前，他在Spark Therapeutics股份有限公司（Spark Therapeutics, Inc.）担任临床研发负责人（2014年）和ViroPharma股份有限公司（ViroPharma, Inc.）临床和临床前开发副总裁（2005-2014年）。Gelone博士也在Vicuron Pharmaceuticals担任医疗事务董事（2002-2003年），也是GlaxoSmithKline Pharmaceuticals临床制药和经验型药物的董事（2000-2002年）。Gelone博士拥有天普大学（Temple University）药学学士学位和博士学位。
- Steven Gelone has served on our board of directors since March 10 2021 and as our president and chief operating officer since July 24 2018. Dr. Gelone previously served as Nabriva Austria’s chief development officer and head of business development from 2014 until the Redomiciliation, our chief development officer from the Redomiciliation until June 30 2017 and our chief scientific officer from June 30 2017 until July 24 2018. Prior to joining Nabriva Austria, he served as head of clinical research and development at Spark Therapeutics, Inc. in 2014 and vice president of clinical and preclinical development at ViroPharma Incorporated from 2005 to 2014. Dr. Gelone also served as director of medical affairs at Vicuron Pharmaceuticals from 2002 to 2003 and director of clinical pharmacology and experimental medicine at GlaxoSmithKline Pharmaceuticals from 2000 to 2002. Dr. Gelone received his B.S. Pharm. and Pharm.D. from Temple University.
- Mark Corrigan
-
Mark Corrigan, M.D.，2015年10月以来，他担任我们董事会成员。他目前担任EPIRUS Biopharmaceuticals, Inc.的董事。他也曾担任其董事（2009年12月以来）和董事长（2014年以来）。2015年以了，他也在 Cardiome Pharma Corp.（上市公司心血管治疗）的董事会任职并在薪酬委员会任职。从2010年1月到2014年7月，Zalicus, Inc.和EPIRUS Biopharmaceuticals两家公司合并，他担任Zalicus, Inc.（ EPIRUS Biopharmaceuticals的前身）的总裁个首席执行官。从2003年4月到2009年12月，他曾是Sunovion Pharmaceuticals Inc.（原Sepracor Inc.）的研发执行副总裁。加入Sunovion Pharmaceuticals之前，他在Pharmacia & Upjohn, Inc.任职10年，最后担任部门副总裁，负责全球临床研究和实验医学。加入制药业之前，他在University of North Carolina Medical School进行学术研究5年，主要从事精神神经内分泌学。从2008年到2015年，他在Cubist Pharmaceuticals, Inc. （被Merck & Co., Inc.收购，上市的生物制药公司），他曾其审计委员会任职。从2014年到2015年，他担任Avanir Pharmaceuticals （被Otsuka Pharmaceutical Company, Ltd.收购，上市公司）的董事会职务，他担任其科学委员会的主席并子啊提名和公司治理委员会任职。
Mark Corrigan has served on our board of directors since June 2 2021. Dr. Corrigan previously served on our board of directors from June 23 2017 to May 26 2020 and prior to the Redomiciliation, Dr. Corrigan served on the supervisory board of Nabriva Austria from October 2016 until the Redomiciliation. Dr. Corrigan was most recently the chief executive officer of Correvio Pharma Corporation formerly Cardiome Pharma, a public biopharmaceutical company, from March 2019 until May 2021. From April 2016 until March 2019 Dr. Corrigan was founder and president of research and development of Tremeau Pharmaceuticals. Dr. Corrigan served as president and chief executive officer of Zalicus, Inc. from January 2010 until July 2014. Previously, Dr. Corrigan was executive vice president of research and development at the specialty pharmaceutical company Sepracor Inc., and prior to this, he spent 10 years with Pharmacia & Upjohn, most recently as group vice president of Global Clinical Research and Experimental Medicine. Dr. Corrigan currently serves on the boards of directors of Wave Biosciences, a public biopharmaceutical company, and Tremeau Pharmaceuticals, a private company. He previously served on the boards of directors of Correvio Pharma Corporation, Novelin Therapeutics, Inc., BlackThorn Therapeutics, Inc., Cubist Pharmaceuticals, Inc., CoLucid Pharmaceuticals, Inc., Avanair Pharmaceuticals, Inc., and EPIRUS Biopharmaceuticals, Inc., where he served as chairman of the board of directors.Dr. Corrigan holds an M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University. - Mark Corrigan, M.D.，2015年10月以来，他担任我们董事会成员。他目前担任EPIRUS Biopharmaceuticals, Inc.的董事。他也曾担任其董事（2009年12月以来）和董事长（2014年以来）。2015年以了，他也在 Cardiome Pharma Corp.（上市公司心血管治疗）的董事会任职并在薪酬委员会任职。从2010年1月到2014年7月，Zalicus, Inc.和EPIRUS Biopharmaceuticals两家公司合并，他担任Zalicus, Inc.（ EPIRUS Biopharmaceuticals的前身）的总裁个首席执行官。从2003年4月到2009年12月，他曾是Sunovion Pharmaceuticals Inc.（原Sepracor Inc.）的研发执行副总裁。加入Sunovion Pharmaceuticals之前，他在Pharmacia & Upjohn, Inc.任职10年，最后担任部门副总裁，负责全球临床研究和实验医学。加入制药业之前，他在University of North Carolina Medical School进行学术研究5年，主要从事精神神经内分泌学。从2008年到2015年，他在Cubist Pharmaceuticals, Inc. （被Merck & Co., Inc.收购，上市的生物制药公司），他曾其审计委员会任职。从2014年到2015年，他担任Avanir Pharmaceuticals （被Otsuka Pharmaceutical Company, Ltd.收购，上市公司）的董事会职务，他担任其科学委员会的主席并子啊提名和公司治理委员会任职。
- Mark Corrigan has served on our board of directors since June 2 2021. Dr. Corrigan previously served on our board of directors from June 23 2017 to May 26 2020 and prior to the Redomiciliation, Dr. Corrigan served on the supervisory board of Nabriva Austria from October 2016 until the Redomiciliation. Dr. Corrigan was most recently the chief executive officer of Correvio Pharma Corporation formerly Cardiome Pharma, a public biopharmaceutical company, from March 2019 until May 2021. From April 2016 until March 2019 Dr. Corrigan was founder and president of research and development of Tremeau Pharmaceuticals. Dr. Corrigan served as president and chief executive officer of Zalicus, Inc. from January 2010 until July 2014. Previously, Dr. Corrigan was executive vice president of research and development at the specialty pharmaceutical company Sepracor Inc., and prior to this, he spent 10 years with Pharmacia & Upjohn, most recently as group vice president of Global Clinical Research and Experimental Medicine. Dr. Corrigan currently serves on the boards of directors of Wave Biosciences, a public biopharmaceutical company, and Tremeau Pharmaceuticals, a private company. He previously served on the boards of directors of Correvio Pharma Corporation, Novelin Therapeutics, Inc., BlackThorn Therapeutics, Inc., Cubist Pharmaceuticals, Inc., CoLucid Pharmaceuticals, Inc., Avanair Pharmaceuticals, Inc., and EPIRUS Biopharmaceuticals, Inc., where he served as chairman of the board of directors.Dr. Corrigan holds an M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University.
- Daniel Burgess
-
Daniel Burgess自2017年6月23日起担任我们的董事会成员。Burgess先生曾担任Nabriva Austria监事会成员，并于2016年10月至Redomicdiscrimination担任其主席。Burgess先生自2014年以来一直担任SV Health Investors SV的风险合伙人。Burgess先生自2019年5月起还担任私人治疗公司Therini Bio，Inc.的总裁兼首席执行官。他曾担任Rempex Pharmaceuticals公司（他于2011年共同创立的抗生素公司，随后于2013年出售给The Medicines Company公司（现为Novartis AG公司））的总裁兼首席执行官。在此之前，Burgess先生从2007年开始担任MPEX Pharmaceuticals的总裁兼首席执行官，直到2011年该公司被Aptalis Inc.（现为艾伯维公司）收购。任职MPEX公司之前，Burgess先生曾担任其他生物技术公司的多种高级运营职务。此外，他还担任CidaraTherapeutics，Inc.（一家上市生物技术公司）、Arbutus Biopharma Corp.（一家上市生物技术公司）和几家私营梦百合公司的董事会成员。Burgess从2004年到2014年担任Santarus，Inc.董事会成员，该公司被上市制药公司Salix Pharmaceuticals Inc.收购。他获得斯坦福大学（Stanford University）的经济学学士学位和哈佛大学（Harvard University）的工商管理硕士学位。
Daniel Burgess has served on our board of directors since June 23 2017. Mr. Burgess was a member of the supervisory board of Nabriva Austria and served as its chairman from October 2016 until the Redomiciliation. Mr. Burgess has been a venture partner at SV Health Investors SV since 2014. Mr. Burgess has also served as the chairman of the board and chief executive officer of Pulmocide Ltd., a private biopharmaceutical company, since May 2021 and the part-time president and chief executive officer of Therini Bio, Inc., a private therapeutics company, since May 2019. He was previously president and chief executive officer of Rempex Pharmaceuticals, an antibiotics company he co-founded in 2011 and that was subsequently sold to The Medicines Company (now Novartis AG) in 2013. Prior to this, Mr. Burgess was president and chief executive officer of Mpex Pharmaceuticals from 2007 until its acquisition by Aptalis Inc. (now AbbVie Inc.) in 2011. Prior to his time at Mpex, Mr. Burgess served in various senior operating roles for other biotechnology companies. In addition, he serves as a member of the boards of directors of Cidara Therapeutics, Inc., a public biotechnology company; Arbutus Biopharma Corp., a public biotechnology company; and several private healthcare companies. Mr. Burgess was a member of the board of directors of Santarus, Inc., from 2004 until its acquisition in 2014 by Salix Pharmaceuticals Inc., a publicly traded pharmaceutical company. He received his B.A. in economics from Stanford University and an M.B.A. from Harvard University. - Daniel Burgess自2017年6月23日起担任我们的董事会成员。Burgess先生曾担任Nabriva Austria监事会成员，并于2016年10月至Redomicdiscrimination担任其主席。Burgess先生自2014年以来一直担任SV Health Investors SV的风险合伙人。Burgess先生自2019年5月起还担任私人治疗公司Therini Bio，Inc.的总裁兼首席执行官。他曾担任Rempex Pharmaceuticals公司（他于2011年共同创立的抗生素公司，随后于2013年出售给The Medicines Company公司（现为Novartis AG公司））的总裁兼首席执行官。在此之前，Burgess先生从2007年开始担任MPEX Pharmaceuticals的总裁兼首席执行官，直到2011年该公司被Aptalis Inc.（现为艾伯维公司）收购。任职MPEX公司之前，Burgess先生曾担任其他生物技术公司的多种高级运营职务。此外，他还担任CidaraTherapeutics，Inc.（一家上市生物技术公司）、Arbutus Biopharma Corp.（一家上市生物技术公司）和几家私营梦百合公司的董事会成员。Burgess从2004年到2014年担任Santarus，Inc.董事会成员，该公司被上市制药公司Salix Pharmaceuticals Inc.收购。他获得斯坦福大学（Stanford University）的经济学学士学位和哈佛大学（Harvard University）的工商管理硕士学位。
- Daniel Burgess has served on our board of directors since June 23 2017. Mr. Burgess was a member of the supervisory board of Nabriva Austria and served as its chairman from October 2016 until the Redomiciliation. Mr. Burgess has been a venture partner at SV Health Investors SV since 2014. Mr. Burgess has also served as the chairman of the board and chief executive officer of Pulmocide Ltd., a private biopharmaceutical company, since May 2021 and the part-time president and chief executive officer of Therini Bio, Inc., a private therapeutics company, since May 2019. He was previously president and chief executive officer of Rempex Pharmaceuticals, an antibiotics company he co-founded in 2011 and that was subsequently sold to The Medicines Company (now Novartis AG) in 2013. Prior to this, Mr. Burgess was president and chief executive officer of Mpex Pharmaceuticals from 2007 until its acquisition by Aptalis Inc. (now AbbVie Inc.) in 2011. Prior to his time at Mpex, Mr. Burgess served in various senior operating roles for other biotechnology companies. In addition, he serves as a member of the boards of directors of Cidara Therapeutics, Inc., a public biotechnology company; Arbutus Biopharma Corp., a public biotechnology company; and several private healthcare companies. Mr. Burgess was a member of the board of directors of Santarus, Inc., from 2004 until its acquisition in 2014 by Salix Pharmaceuticals Inc., a publicly traded pharmaceutical company. He received his B.A. in economics from Stanford University and an M.B.A. from Harvard University.
- Stephen Webster
-
Stephen Webster自2020年9月以来一直担任我们的董事会成员。韦伯斯特先生从2014年7月起担任星火治疗公司的首席财务官，直到2019年12月该公司被罗氏控股（Roche Holding AG）以48亿美元收购。他此前曾担任Optimer Pharmaceuticals公司的高级副总裁兼首席财务官（从2012年7月到2013年10月被Cubist Pharmaceuticals公司收购）。Webster先生目前在NextCure，Inc.公司董事会任职。纳斯达克市场代码:NXTC，Nabriva Therapeutics AG（原Nabriva Therapeutics plc）（纳斯达克市场代码:NBRV）和TCR2（纳斯达克市场代码:TCRR）。Webster先生在达特茅斯学院（Dartmouth College）获得经济学学士学位，并在宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）获得金融学工商管理硕士学位。
Stephen Webster,Mr. Webster has served as a member of Cullinan Oncology, Inc. board of directors since September 2020. Mr. Webster served as the Chief Financial Officer of Spark Therapeutics, Inc., a gene therapy company, from July 2014 until its acquisition by Roche Holding AG for $4.8 billion in December 2019. He was previously Senior Vice President and Chief Financial Officer of Optimer Pharmaceuticals Inc. from July 2012 until its acquisition by Cubist Pharmaceuticals Inc. in October 2013. Mr. Webster currently serves on the board of directors of NextCure, Inc., Nabriva Therapeutics AG (formerly Nabriva Therapeutics plc) and TCR2. Mr. Webster received an A.B. in Economics from Dartmouth College and an M.B.A. in Finance from The Wharton School of the University of Pennsylvania. - Stephen Webster自2020年9月以来一直担任我们的董事会成员。韦伯斯特先生从2014年7月起担任星火治疗公司的首席财务官，直到2019年12月该公司被罗氏控股（Roche Holding AG）以48亿美元收购。他此前曾担任Optimer Pharmaceuticals公司的高级副总裁兼首席财务官（从2012年7月到2013年10月被Cubist Pharmaceuticals公司收购）。Webster先生目前在NextCure，Inc.公司董事会任职。纳斯达克市场代码:NXTC，Nabriva Therapeutics AG（原Nabriva Therapeutics plc）（纳斯达克市场代码:NBRV）和TCR2（纳斯达克市场代码:TCRR）。Webster先生在达特茅斯学院（Dartmouth College）获得经济学学士学位，并在宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）获得金融学工商管理硕士学位。
- Stephen Webster,Mr. Webster has served as a member of Cullinan Oncology, Inc. board of directors since September 2020. Mr. Webster served as the Chief Financial Officer of Spark Therapeutics, Inc., a gene therapy company, from July 2014 until its acquisition by Roche Holding AG for $4.8 billion in December 2019. He was previously Senior Vice President and Chief Financial Officer of Optimer Pharmaceuticals Inc. from July 2012 until its acquisition by Cubist Pharmaceuticals Inc. in October 2013. Mr. Webster currently serves on the board of directors of NextCure, Inc., Nabriva Therapeutics AG (formerly Nabriva Therapeutics plc) and TCR2. Mr. Webster received an A.B. in Economics from Dartmouth College and an M.B.A. in Finance from The Wharton School of the University of Pennsylvania.
- Carrie Bourdow
-
Carrie Bourdow自2017年6月23日起担任我们的董事会成员。Bourdow女士自2018年10月起担任上市生物制药公司Trevena，Inc.的总裁，首席执行官和董事会成员。2015年5月以来，她曾担任Trevena公司的多种高级职务。她加入Trevena担任首席商务官，并于2018年1月被任命为执行Vice President兼首席运营官。在加入Trevena之前，Bourdow女士从2013年到2015年1月被默克制药公司收购，一直担任CubistPharmaceuticals，Inc.营销Vice President。在Cubist，Bourdow女士领导了Acute Care Hospital Pharmaceuticals的启动战略，营销，报销和运营。在加入Cubist之前，Bourdow女士在默克制药公司工作了20多年，在那里她在多个治疗领域担任着越来越重要的职务。Bourdow女士还担任SesenBio，Inc.的董事，该公司是一家公开上市的制药公司。Bourdow女士拥有Hendrix College的学士学位和Southern Illinois University的工商管理硕士学位。
Carrie Bourdow has served on our board of directors since June 23 2017. Ms. Bourdow has been the president, the chief executive officer, and member of the board of directors of Trevena, Inc., a publicly-traded biopharmaceutical company, since October 2018. She has served in various senior positions at Trevena since May 2015. She joined Trevena as chief commercial officer and was appointed executive vice president and chief operating officer in January 2018. Prior to joining Trevena, Ms. Bourdow was vice president of marketing at Cubist Pharmaceuticals, Inc., from 2013 until its acquisition by Merck & Co., Inc. in January 2015. At Cubist, Ms. Bourdow led launch strategy, marketing, reimbursement, and operations for acute care hospital pharmaceuticals. Prior to Cubist, Ms. Bourdow served for more than 20 years at Merck & Co., Inc., where she held positions of increasing responsibility across multiple therapeutic areas. Ms. Bourdow also serves as a director of Sesen Bio, Inc., a publicly traded pharmaceutical company. Ms. Bourdow holds a B.A. degree from Hendrix College and an M.B.A. from Southern Illinois University. - Carrie Bourdow自2017年6月23日起担任我们的董事会成员。Bourdow女士自2018年10月起担任上市生物制药公司Trevena，Inc.的总裁，首席执行官和董事会成员。2015年5月以来，她曾担任Trevena公司的多种高级职务。她加入Trevena担任首席商务官，并于2018年1月被任命为执行Vice President兼首席运营官。在加入Trevena之前，Bourdow女士从2013年到2015年1月被默克制药公司收购，一直担任CubistPharmaceuticals，Inc.营销Vice President。在Cubist，Bourdow女士领导了Acute Care Hospital Pharmaceuticals的启动战略，营销，报销和运营。在加入Cubist之前，Bourdow女士在默克制药公司工作了20多年，在那里她在多个治疗领域担任着越来越重要的职务。Bourdow女士还担任SesenBio，Inc.的董事，该公司是一家公开上市的制药公司。Bourdow女士拥有Hendrix College的学士学位和Southern Illinois University的工商管理硕士学位。
- Carrie Bourdow has served on our board of directors since June 23 2017. Ms. Bourdow has been the president, the chief executive officer, and member of the board of directors of Trevena, Inc., a publicly-traded biopharmaceutical company, since October 2018. She has served in various senior positions at Trevena since May 2015. She joined Trevena as chief commercial officer and was appointed executive vice president and chief operating officer in January 2018. Prior to joining Trevena, Ms. Bourdow was vice president of marketing at Cubist Pharmaceuticals, Inc., from 2013 until its acquisition by Merck & Co., Inc. in January 2015. At Cubist, Ms. Bourdow led launch strategy, marketing, reimbursement, and operations for acute care hospital pharmaceuticals. Prior to Cubist, Ms. Bourdow served for more than 20 years at Merck & Co., Inc., where she held positions of increasing responsibility across multiple therapeutic areas. Ms. Bourdow also serves as a director of Sesen Bio, Inc., a publicly traded pharmaceutical company. Ms. Bourdow holds a B.A. degree from Hendrix College and an M.B.A. from Southern Illinois University.
- Theodore Schroeder
-
Theodore Schroeder自2018年7月24日起担任我们的董事会成员和首席执行官。在过去的30年中，Schroeder先生一直专注于大型和小型制药公司的药物开发和商业化。最近，他于2015年6月起担任Zavante Therapeutics的总裁，首席执行官兼董事，直到2018年7月被Nabriva Therapeutics收购。Schroeder先生于2004年共同创立了Cadence Pharmaceuticals，此前曾在Elan Pharmaceuticals，Dura Pharmaceuticals以及职业生涯早期的Bristol-Myers Squibb担任领导职务。他目前任职于Cidara Therapeutics公司、Otonomy公司和Collegium Pharmaceutical公司的董事会。他是Biocom公司（加州生命科学贸易协会）的前任主席，并于2014年被评为圣地亚哥地区的EY年度企业家，并被列为国家入围名单。他获得罗格斯大学（Rutgers University）管理学士学位。
Theodore Schroeder has served on our board of directors and as chief executive officer since July 24 2018. During the last 30 years, Mr. Schroeder has been focused on drug development and commercialization in both large and small pharmaceutical companies. Most recently, he served as president, chief executive officer and director of Zavante Therapeutics from June 2015 until its acquisition by Nabriva Therapeutics in July 2018. Mr. Schroeder co-founded Cadence Pharmaceuticals in 2004 and previously held leadership roles at Elan Pharmaceuticals, Dura Pharmaceuticals and earlier in his career, Bristol-Myers Squibb. He currently serves on the board of Cidara Therapeutics, Otonomy and Collegium Pharmaceutical. He is a former chair of BIOCOM, the California life sciences trade association and in 2014 he was named the EY Entrepreneur of the Year for the San Diego region and was listed as a national finalist. He received a bachelor’s degree in management from Rutgers University. - Theodore Schroeder自2018年7月24日起担任我们的董事会成员和首席执行官。在过去的30年中，Schroeder先生一直专注于大型和小型制药公司的药物开发和商业化。最近，他于2015年6月起担任Zavante Therapeutics的总裁，首席执行官兼董事，直到2018年7月被Nabriva Therapeutics收购。Schroeder先生于2004年共同创立了Cadence Pharmaceuticals，此前曾在Elan Pharmaceuticals，Dura Pharmaceuticals以及职业生涯早期的Bristol-Myers Squibb担任领导职务。他目前任职于Cidara Therapeutics公司、Otonomy公司和Collegium Pharmaceutical公司的董事会。他是Biocom公司（加州生命科学贸易协会）的前任主席，并于2014年被评为圣地亚哥地区的EY年度企业家，并被列为国家入围名单。他获得罗格斯大学（Rutgers University）管理学士学位。
- Theodore Schroeder has served on our board of directors and as chief executive officer since July 24 2018. During the last 30 years, Mr. Schroeder has been focused on drug development and commercialization in both large and small pharmaceutical companies. Most recently, he served as president, chief executive officer and director of Zavante Therapeutics from June 2015 until its acquisition by Nabriva Therapeutics in July 2018. Mr. Schroeder co-founded Cadence Pharmaceuticals in 2004 and previously held leadership roles at Elan Pharmaceuticals, Dura Pharmaceuticals and earlier in his career, Bristol-Myers Squibb. He currently serves on the board of Cidara Therapeutics, Otonomy and Collegium Pharmaceutical. He is a former chair of BIOCOM, the California life sciences trade association and in 2014 he was named the EY Entrepreneur of the Year for the San Diego region and was listed as a national finalist. He received a bachelor’s degree in management from Rutgers University.
- Charles A. Rowland, Jr.
-
Charles A. Rowland, Jr.（小），2014年9月起成为公司董事会成员。目前他担任战略顾问。2008年10月起到2014年1月公司被Shire plc收购，他担任国际制药公司ViroPharma Incorporated的副总裁兼首席财务官。加入ViroPharma前，2006年12月至2008年9月，他曾是Endo Pharmaceuticals Inc.的执行副总裁、首席财务官和临时联合首席执行官，该公司是一家疼痛管理专业制药公司。2004年至2006年，他担任国际制药公司Biovail Corporation的高级副总裁兼首席财务官。之前，他也曾在Breakaway Technologies公司、Pharmacia Corporation、Novartis AG 和Bristol-Myers Squibb Co。任职。目前他任职于BIND Therapeutics公司和Aurina Pharmaceuticals公司的董事会。2013年至2014年8月公司被默克（Merck & Co., Inc.）收购期间，他任职于Idenix Pharmaceuticals公司的董事会。他同时也是费城Financial Executives International的董事会成员。他取得了圣约瑟夫大学（St. Joseph's University）会计学士和罗格斯大学（Rutgers University）工商管理硕士学位。
Charles A. Rowland, Jr. has served on our board of directors since June 23 2017. Mr. Rowland previously served on the supervisory board of Nabriva Austria from January 2015 until the Redomiciliation. Mr. Rowland served as chief executive officer of Aurinia Pharmaceuticals Inc. from April 2016 to January 2017. Mr. Rowland previously served as vice president and chief financial officer of ViroPharma Incorporated from 2008 until it was acquired by Shire plc in 2014. Prior to joining ViroPharma, Mr. Rowland served as executive vice president and chief financial officer, as well as interim co-chief executive officer, for Endo Pharmaceuticals Inc. from 2006 to 2008 and chief financial officer at Biovail Corporation from 2004 to 2006. He previously held finance and operational positions of increasing responsibility at Breakaway Technologies, Inc., Pharmacia, Novartis International AG and Bristol-Myers Squibb Company. Mr. Rowland currently serves as a member of the board of directors for Blueprint Medicines Corporation, a public biopharmaceutical company, Viking Therapeutics, a public, clinical-stage biopharmaceutical company, and Orchard Therapeutics, a public, clinical-stage biopharmaceutical company. In addition, Mr. Rowland serves as a member of the board of directors for Generation Bio, a privately held biopharmaceutical company. Previously, he served on the board of directors at Idenix Pharmaceuticals, Inc., Vitae Pharmaceuticals, Inc., Bind Therapeutics Inc. and Aurinia Pharmaceuticals Inc. Mr. Rowland received his B.S. from Saint Joseph’s University and M.B.A. from Rutgers University. - Charles A. Rowland, Jr.（小），2014年9月起成为公司董事会成员。目前他担任战略顾问。2008年10月起到2014年1月公司被Shire plc收购，他担任国际制药公司ViroPharma Incorporated的副总裁兼首席财务官。加入ViroPharma前，2006年12月至2008年9月，他曾是Endo Pharmaceuticals Inc.的执行副总裁、首席财务官和临时联合首席执行官，该公司是一家疼痛管理专业制药公司。2004年至2006年，他担任国际制药公司Biovail Corporation的高级副总裁兼首席财务官。之前，他也曾在Breakaway Technologies公司、Pharmacia Corporation、Novartis AG 和Bristol-Myers Squibb Co。任职。目前他任职于BIND Therapeutics公司和Aurina Pharmaceuticals公司的董事会。2013年至2014年8月公司被默克（Merck & Co., Inc.）收购期间，他任职于Idenix Pharmaceuticals公司的董事会。他同时也是费城Financial Executives International的董事会成员。他取得了圣约瑟夫大学（St. Joseph's University）会计学士和罗格斯大学（Rutgers University）工商管理硕士学位。
- Charles A. Rowland, Jr. has served on our board of directors since June 23 2017. Mr. Rowland previously served on the supervisory board of Nabriva Austria from January 2015 until the Redomiciliation. Mr. Rowland served as chief executive officer of Aurinia Pharmaceuticals Inc. from April 2016 to January 2017. Mr. Rowland previously served as vice president and chief financial officer of ViroPharma Incorporated from 2008 until it was acquired by Shire plc in 2014. Prior to joining ViroPharma, Mr. Rowland served as executive vice president and chief financial officer, as well as interim co-chief executive officer, for Endo Pharmaceuticals Inc. from 2006 to 2008 and chief financial officer at Biovail Corporation from 2004 to 2006. He previously held finance and operational positions of increasing responsibility at Breakaway Technologies, Inc., Pharmacia, Novartis International AG and Bristol-Myers Squibb Company. Mr. Rowland currently serves as a member of the board of directors for Blueprint Medicines Corporation, a public biopharmaceutical company, Viking Therapeutics, a public, clinical-stage biopharmaceutical company, and Orchard Therapeutics, a public, clinical-stage biopharmaceutical company. In addition, Mr. Rowland serves as a member of the board of directors for Generation Bio, a privately held biopharmaceutical company. Previously, he served on the board of directors at Idenix Pharmaceuticals, Inc., Vitae Pharmaceuticals, Inc., Bind Therapeutics Inc. and Aurinia Pharmaceuticals Inc. Mr. Rowland received his B.S. from Saint Joseph’s University and M.B.A. from Rutgers University.
- Colin Broom
-
自2009年7月起，Colin Broom担任董事。自2004年以来，他一直担任ViroPharma, Inc副总裁，首席科学官，负责公司所有的研发和医疗事务活动，这是一家上市生物制药公司致力于以解决由医生和专家在医院治疗的严重疾病的产品的开发和商业化，公司于2014年1月被 Shire plc 收购。从2000年到2003年，他曾担任Amgen 欧洲临床开发和医疗事务的副总裁。在加入Amgen前，他是 Hoechst Marion Roussel现为 Sanofi 临床开发副总裁，并在Glaxo以及 SmithKline Beecham （现为GlaxoSmithKline）任职14年，他在领导职位任要职，包括任global oncology负责人，以及 CNS/GI副总裁。 他拥有 University College, London 药理学学士学位，St. George's Hospital Medical School, London医学及外科学士学位。他是Royal College of Physicians 的成员和Pharmaceutical Medicine of the UK Colleges of Physicians院士。
Colin Broom has served on our board of directors since June 23 2017. Dr. Broom has served as the chief executive officer of Pulmotect, Inc., a private biotechnology company, since September 2019. Dr. Broom was previously our chief executive officer from April 12 2017 until July 24 2018 and the chief executive officer of Nabriva Austria from August 2014 until the Redomiciliation. Prior to joining Nabriva Austria, he served as chief scientific officer at ViroPharma Incorporated from 2004 until it was acquired by Shire plc in 2014. Dr. Broom served as vice president of clinical development and medical affairs in Europe for Amgen Inc. from 2000 to 2003 and previously held several leadership positions with Hoechst Marion Roussel now Sanofi, SmithKline Beecham and Glaxo (now GlaxoSmithKline). Dr. Broom served as a member of the board of directors of NPS Pharmaceuticals, Inc. from 2009 until its acquisition by Shire in 2015. He is a member of the U.K. Royal College of Physicians and a fellow of the Faculty of Pharmaceutical Medicine. Dr. Broom received his B.Sc. from University College, London and M.B.B.S. from St. George’s Hospital Medical School, London. - 自2009年7月起，Colin Broom担任董事。自2004年以来，他一直担任ViroPharma, Inc副总裁，首席科学官，负责公司所有的研发和医疗事务活动，这是一家上市生物制药公司致力于以解决由医生和专家在医院治疗的严重疾病的产品的开发和商业化，公司于2014年1月被 Shire plc 收购。从2000年到2003年，他曾担任Amgen 欧洲临床开发和医疗事务的副总裁。在加入Amgen前，他是 Hoechst Marion Roussel现为 Sanofi 临床开发副总裁，并在Glaxo以及 SmithKline Beecham （现为GlaxoSmithKline）任职14年，他在领导职位任要职，包括任global oncology负责人，以及 CNS/GI副总裁。 他拥有 University College, London 药理学学士学位，St. George's Hospital Medical School, London医学及外科学士学位。他是Royal College of Physicians 的成员和Pharmaceutical Medicine of the UK Colleges of Physicians院士。
- Colin Broom has served on our board of directors since June 23 2017. Dr. Broom has served as the chief executive officer of Pulmotect, Inc., a private biotechnology company, since September 2019. Dr. Broom was previously our chief executive officer from April 12 2017 until July 24 2018 and the chief executive officer of Nabriva Austria from August 2014 until the Redomiciliation. Prior to joining Nabriva Austria, he served as chief scientific officer at ViroPharma Incorporated from 2004 until it was acquired by Shire plc in 2014. Dr. Broom served as vice president of clinical development and medical affairs in Europe for Amgen Inc. from 2000 to 2003 and previously held several leadership positions with Hoechst Marion Roussel now Sanofi, SmithKline Beecham and Glaxo (now GlaxoSmithKline). Dr. Broom served as a member of the board of directors of NPS Pharmaceuticals, Inc. from 2009 until its acquisition by Shire in 2015. He is a member of the U.K. Royal College of Physicians and a fellow of the Faculty of Pharmaceutical Medicine. Dr. Broom received his B.Sc. from University College, London and M.B.B.S. from St. George’s Hospital Medical School, London.
高管简历
中英对照 | 中文 | 英文- Steven Gelone
Steven Gelone自2014年起担任公司的首席发展官。再加入公司之前，他在Spark Therapeutics股份有限公司（Spark Therapeutics, Inc.）担任临床研发负责人（2014年）和ViroPharma股份有限公司（ViroPharma, Inc.）临床和临床前开发副总裁（2005-2014年）。Gelone博士也在Vicuron Pharmaceuticals担任医疗事务董事（2002-2003年），也是GlaxoSmithKline Pharmaceuticals临床制药和经验型药物的董事（2000-2002年）。Gelone博士拥有天普大学（Temple University）药学学士学位和博士学位。
Steven Gelone has served on our board of directors since March 10 2021 and as our president and chief operating officer since July 24 2018. Dr. Gelone previously served as Nabriva Austria’s chief development officer and head of business development from 2014 until the Redomiciliation, our chief development officer from the Redomiciliation until June 30 2017 and our chief scientific officer from June 30 2017 until July 24 2018. Prior to joining Nabriva Austria, he served as head of clinical research and development at Spark Therapeutics, Inc. in 2014 and vice president of clinical and preclinical development at ViroPharma Incorporated from 2005 to 2014. Dr. Gelone also served as director of medical affairs at Vicuron Pharmaceuticals from 2002 to 2003 and director of clinical pharmacology and experimental medicine at GlaxoSmithKline Pharmaceuticals from 2000 to 2002. Dr. Gelone received his B.S. Pharm. and Pharm.D. from Temple University.- Steven Gelone自2014年起担任公司的首席发展官。再加入公司之前，他在Spark Therapeutics股份有限公司（Spark Therapeutics, Inc.）担任临床研发负责人（2014年）和ViroPharma股份有限公司（ViroPharma, Inc.）临床和临床前开发副总裁（2005-2014年）。Gelone博士也在Vicuron Pharmaceuticals担任医疗事务董事（2002-2003年），也是GlaxoSmithKline Pharmaceuticals临床制药和经验型药物的董事（2000-2002年）。Gelone博士拥有天普大学（Temple University）药学学士学位和博士学位。
- Steven Gelone has served on our board of directors since March 10 2021 and as our president and chief operating officer since July 24 2018. Dr. Gelone previously served as Nabriva Austria’s chief development officer and head of business development from 2014 until the Redomiciliation, our chief development officer from the Redomiciliation until June 30 2017 and our chief scientific officer from June 30 2017 until July 24 2018. Prior to joining Nabriva Austria, he served as head of clinical research and development at Spark Therapeutics, Inc. in 2014 and vice president of clinical and preclinical development at ViroPharma Incorporated from 2005 to 2014. Dr. Gelone also served as director of medical affairs at Vicuron Pharmaceuticals from 2002 to 2003 and director of clinical pharmacology and experimental medicine at GlaxoSmithKline Pharmaceuticals from 2000 to 2002. Dr. Gelone received his B.S. Pharm. and Pharm.D. from Temple University.
- Daniel Burgess
Daniel Burgess自2017年6月23日起担任我们的董事会成员。Burgess先生曾担任Nabriva Austria监事会成员，并于2016年10月至Redomicdiscrimination担任其主席。Burgess先生自2014年以来一直担任SV Health Investors SV的风险合伙人。Burgess先生自2019年5月起还担任私人治疗公司Therini Bio，Inc.的总裁兼首席执行官。他曾担任Rempex Pharmaceuticals公司（他于2011年共同创立的抗生素公司，随后于2013年出售给The Medicines Company公司（现为Novartis AG公司））的总裁兼首席执行官。在此之前，Burgess先生从2007年开始担任MPEX Pharmaceuticals的总裁兼首席执行官，直到2011年该公司被Aptalis Inc.（现为艾伯维公司）收购。任职MPEX公司之前，Burgess先生曾担任其他生物技术公司的多种高级运营职务。此外，他还担任CidaraTherapeutics，Inc.（一家上市生物技术公司）、Arbutus Biopharma Corp.（一家上市生物技术公司）和几家私营梦百合公司的董事会成员。Burgess从2004年到2014年担任Santarus，Inc.董事会成员，该公司被上市制药公司Salix Pharmaceuticals Inc.收购。他获得斯坦福大学（Stanford University）的经济学学士学位和哈佛大学（Harvard University）的工商管理硕士学位。
Daniel Burgess has served on our board of directors since June 23 2017. Mr. Burgess was a member of the supervisory board of Nabriva Austria and served as its chairman from October 2016 until the Redomiciliation. Mr. Burgess has been a venture partner at SV Health Investors SV since 2014. Mr. Burgess has also served as the chairman of the board and chief executive officer of Pulmocide Ltd., a private biopharmaceutical company, since May 2021 and the part-time president and chief executive officer of Therini Bio, Inc., a private therapeutics company, since May 2019. He was previously president and chief executive officer of Rempex Pharmaceuticals, an antibiotics company he co-founded in 2011 and that was subsequently sold to The Medicines Company (now Novartis AG) in 2013. Prior to this, Mr. Burgess was president and chief executive officer of Mpex Pharmaceuticals from 2007 until its acquisition by Aptalis Inc. (now AbbVie Inc.) in 2011. Prior to his time at Mpex, Mr. Burgess served in various senior operating roles for other biotechnology companies. In addition, he serves as a member of the boards of directors of Cidara Therapeutics, Inc., a public biotechnology company; Arbutus Biopharma Corp., a public biotechnology company; and several private healthcare companies. Mr. Burgess was a member of the board of directors of Santarus, Inc., from 2004 until its acquisition in 2014 by Salix Pharmaceuticals Inc., a publicly traded pharmaceutical company. He received his B.A. in economics from Stanford University and an M.B.A. from Harvard University.- Daniel Burgess自2017年6月23日起担任我们的董事会成员。Burgess先生曾担任Nabriva Austria监事会成员，并于2016年10月至Redomicdiscrimination担任其主席。Burgess先生自2014年以来一直担任SV Health Investors SV的风险合伙人。Burgess先生自2019年5月起还担任私人治疗公司Therini Bio，Inc.的总裁兼首席执行官。他曾担任Rempex Pharmaceuticals公司（他于2011年共同创立的抗生素公司，随后于2013年出售给The Medicines Company公司（现为Novartis AG公司））的总裁兼首席执行官。在此之前，Burgess先生从2007年开始担任MPEX Pharmaceuticals的总裁兼首席执行官，直到2011年该公司被Aptalis Inc.（现为艾伯维公司）收购。任职MPEX公司之前，Burgess先生曾担任其他生物技术公司的多种高级运营职务。此外，他还担任CidaraTherapeutics，Inc.（一家上市生物技术公司）、Arbutus Biopharma Corp.（一家上市生物技术公司）和几家私营梦百合公司的董事会成员。Burgess从2004年到2014年担任Santarus，Inc.董事会成员，该公司被上市制药公司Salix Pharmaceuticals Inc.收购。他获得斯坦福大学（Stanford University）的经济学学士学位和哈佛大学（Harvard University）的工商管理硕士学位。
- Daniel Burgess has served on our board of directors since June 23 2017. Mr. Burgess was a member of the supervisory board of Nabriva Austria and served as its chairman from October 2016 until the Redomiciliation. Mr. Burgess has been a venture partner at SV Health Investors SV since 2014. Mr. Burgess has also served as the chairman of the board and chief executive officer of Pulmocide Ltd., a private biopharmaceutical company, since May 2021 and the part-time president and chief executive officer of Therini Bio, Inc., a private therapeutics company, since May 2019. He was previously president and chief executive officer of Rempex Pharmaceuticals, an antibiotics company he co-founded in 2011 and that was subsequently sold to The Medicines Company (now Novartis AG) in 2013. Prior to this, Mr. Burgess was president and chief executive officer of Mpex Pharmaceuticals from 2007 until its acquisition by Aptalis Inc. (now AbbVie Inc.) in 2011. Prior to his time at Mpex, Mr. Burgess served in various senior operating roles for other biotechnology companies. In addition, he serves as a member of the boards of directors of Cidara Therapeutics, Inc., a public biotechnology company; Arbutus Biopharma Corp., a public biotechnology company; and several private healthcare companies. Mr. Burgess was a member of the board of directors of Santarus, Inc., from 2004 until its acquisition in 2014 by Salix Pharmaceuticals Inc., a publicly traded pharmaceutical company. He received his B.A. in economics from Stanford University and an M.B.A. from Harvard University.
- Robert Crotty
Robert Crotty自2017年6月23日起担任我们的总法律顾问兼秘书。Crotty先生于2017年6月14日重新定居之前加入Nabriva Australia担任总法律顾问兼秘书。此前，克罗蒂曾于2016年1月至2017年6月担任Vernalis Therapeutics，Inc.的Vice President、总法律顾问、首席合规官和秘书。在加入Vernalis之前，克罗蒂曾于2012年4月至2015年7月在Dendreon Corporation担任多个职位，包括2015年2月至2015年7月担任总裁、总法律顾问兼秘书，2014年3月至2015年2月担任执行Vice President、总法律顾问兼秘书，以及Vice President，2012年4月至2014年2月，担任助理总法律顾问兼助理秘书。加入Dendreon之前，Crotty从2009年到2012年担任NPS Pharmaceuticals高级法律顾问，从2006年到2009年担任ImClone Systems，Inc.高级法律顾问。在加入公司之前，Crotty先生是Morgan，Lewis&Bockius和Norton Rose Fulbright的合伙人。Crotty先生在普林斯顿大学（Princeton University）获得学士学位，在宾夕法尼亚大学（University of Pennsylvania）获得法学博士学位。
Robert Crotty has served as our general counsel and secretary since June 23 2017. Mr. Crotty joined Nabriva Austria as general counsel and secretary prior to the Redomiciliation on June 14 2017. Previously, Mr. Crotty served as vice president, general counsel, chief compliance officer and secretary of Vernalis Therapeutics, Inc. from January 2016 to June 2017. Prior to joining Vernalis, Mr. Crotty held several positions at Dendreon Corporation from April 2012 to July 2015 including president, general counsel and secretary from February 2015 to July 2015 executive vice president, general counsel and secretary from March 2014 to February 2015 and vice president, assistant general counsel and assistant secretary from April 2012 to February 2014. Before Dendreon, Mr. Crotty was senior counsel at NPS Pharmaceuticals from 2009 until 2012 and at ImClone Systems, Inc. from 2006 to 2009. Prior to going in-house, Mr. Crotty was an associate at Morgan, Lewis & Bockius and Norton Rose Fulbright. Mr. Crotty received his B.A. from Princeton University and J.D. from University of Pennsylvania.- Robert Crotty自2017年6月23日起担任我们的总法律顾问兼秘书。Crotty先生于2017年6月14日重新定居之前加入Nabriva Australia担任总法律顾问兼秘书。此前，克罗蒂曾于2016年1月至2017年6月担任Vernalis Therapeutics，Inc.的Vice President、总法律顾问、首席合规官和秘书。在加入Vernalis之前，克罗蒂曾于2012年4月至2015年7月在Dendreon Corporation担任多个职位，包括2015年2月至2015年7月担任总裁、总法律顾问兼秘书，2014年3月至2015年2月担任执行Vice President、总法律顾问兼秘书，以及Vice President，2012年4月至2014年2月，担任助理总法律顾问兼助理秘书。加入Dendreon之前，Crotty从2009年到2012年担任NPS Pharmaceuticals高级法律顾问，从2006年到2009年担任ImClone Systems，Inc.高级法律顾问。在加入公司之前，Crotty先生是Morgan，Lewis&Bockius和Norton Rose Fulbright的合伙人。Crotty先生在普林斯顿大学（Princeton University）获得学士学位，在宾夕法尼亚大学（University of Pennsylvania）获得法学博士学位。
- Robert Crotty has served as our general counsel and secretary since June 23 2017. Mr. Crotty joined Nabriva Austria as general counsel and secretary prior to the Redomiciliation on June 14 2017. Previously, Mr. Crotty served as vice president, general counsel, chief compliance officer and secretary of Vernalis Therapeutics, Inc. from January 2016 to June 2017. Prior to joining Vernalis, Mr. Crotty held several positions at Dendreon Corporation from April 2012 to July 2015 including president, general counsel and secretary from February 2015 to July 2015 executive vice president, general counsel and secretary from March 2014 to February 2015 and vice president, assistant general counsel and assistant secretary from April 2012 to February 2014. Before Dendreon, Mr. Crotty was senior counsel at NPS Pharmaceuticals from 2009 until 2012 and at ImClone Systems, Inc. from 2006 to 2009. Prior to going in-house, Mr. Crotty was an associate at Morgan, Lewis & Bockius and Norton Rose Fulbright. Mr. Crotty received his B.A. from Princeton University and J.D. from University of Pennsylvania.
- Theodore Schroeder
Theodore Schroeder自2018年7月24日起担任我们的董事会成员和首席执行官。在过去的30年中，Schroeder先生一直专注于大型和小型制药公司的药物开发和商业化。最近，他于2015年6月起担任Zavante Therapeutics的总裁，首席执行官兼董事，直到2018年7月被Nabriva Therapeutics收购。Schroeder先生于2004年共同创立了Cadence Pharmaceuticals，此前曾在Elan Pharmaceuticals，Dura Pharmaceuticals以及职业生涯早期的Bristol-Myers Squibb担任领导职务。他目前任职于Cidara Therapeutics公司、Otonomy公司和Collegium Pharmaceutical公司的董事会。他是Biocom公司（加州生命科学贸易协会）的前任主席，并于2014年被评为圣地亚哥地区的EY年度企业家，并被列为国家入围名单。他获得罗格斯大学（Rutgers University）管理学士学位。
Theodore Schroeder has served on our board of directors and as chief executive officer since July 24 2018. During the last 30 years, Mr. Schroeder has been focused on drug development and commercialization in both large and small pharmaceutical companies. Most recently, he served as president, chief executive officer and director of Zavante Therapeutics from June 2015 until its acquisition by Nabriva Therapeutics in July 2018. Mr. Schroeder co-founded Cadence Pharmaceuticals in 2004 and previously held leadership roles at Elan Pharmaceuticals, Dura Pharmaceuticals and earlier in his career, Bristol-Myers Squibb. He currently serves on the board of Cidara Therapeutics, Otonomy and Collegium Pharmaceutical. He is a former chair of BIOCOM, the California life sciences trade association and in 2014 he was named the EY Entrepreneur of the Year for the San Diego region and was listed as a national finalist. He received a bachelor’s degree in management from Rutgers University.- Theodore Schroeder自2018年7月24日起担任我们的董事会成员和首席执行官。在过去的30年中，Schroeder先生一直专注于大型和小型制药公司的药物开发和商业化。最近，他于2015年6月起担任Zavante Therapeutics的总裁，首席执行官兼董事，直到2018年7月被Nabriva Therapeutics收购。Schroeder先生于2004年共同创立了Cadence Pharmaceuticals，此前曾在Elan Pharmaceuticals，Dura Pharmaceuticals以及职业生涯早期的Bristol-Myers Squibb担任领导职务。他目前任职于Cidara Therapeutics公司、Otonomy公司和Collegium Pharmaceutical公司的董事会。他是Biocom公司（加州生命科学贸易协会）的前任主席，并于2014年被评为圣地亚哥地区的EY年度企业家，并被列为国家入围名单。他获得罗格斯大学（Rutgers University）管理学士学位。
- Theodore Schroeder has served on our board of directors and as chief executive officer since July 24 2018. During the last 30 years, Mr. Schroeder has been focused on drug development and commercialization in both large and small pharmaceutical companies. Most recently, he served as president, chief executive officer and director of Zavante Therapeutics from June 2015 until its acquisition by Nabriva Therapeutics in July 2018. Mr. Schroeder co-founded Cadence Pharmaceuticals in 2004 and previously held leadership roles at Elan Pharmaceuticals, Dura Pharmaceuticals and earlier in his career, Bristol-Myers Squibb. He currently serves on the board of Cidara Therapeutics, Otonomy and Collegium Pharmaceutical. He is a former chair of BIOCOM, the California life sciences trade association and in 2014 he was named the EY Entrepreneur of the Year for the San Diego region and was listed as a national finalist. He received a bachelor’s degree in management from Rutgers University.
- Daniel Dolan
Daniel Dolan自2021年3月12日起担任公司首席财务官。Dolan先生曾于2017年7月至2021年1月担任商业阶段生物制药公司RadiusHealth，Inc.或Radius的财务副总裁。从2020年9月至2020年12月，他还担任Radius的首席财务官和首席会计官。在加入Radius之前，Dolan先生于2005年9月至2017年7月在Shire plc工作，在那里他担任越来越重要的财务管理职务，包括2016年5月至2017年7月担任财务副总裁，全球产品战略和高级财务总监，2013年5月至2016年5月，GI/内科。Dolan先生获得了Widener大学的工商管理硕士和工商管理硕士学位。
Daniel Dolan has served as our chief financial officer since March 12 2021. Mr. Dolan previously served as Vice President of Finance at Radius Health, Inc., or Radius, a commercial-stage biopharmaceutical company, from July 2017 to January 2021. He also acted as principal financial officer and principal accounting officer of Radius from September 2020 to December 2020. Prior to joining Radius, Mr. Dolan worked at Shire plc from September 2005 to July 2017 where he held financial management positions of increasing responsibility, including Vice President of Finance, Global Product Strategy from May 2016 to July 2017 and Senior Finance Director, GI/Internal Medicine from May 2013 to May 2016. Mr. Dolan received his M.B.A. and B.S. from Widener University.- Daniel Dolan自2021年3月12日起担任公司首席财务官。Dolan先生曾于2017年7月至2021年1月担任商业阶段生物制药公司RadiusHealth，Inc.或Radius的财务副总裁。从2020年9月至2020年12月，他还担任Radius的首席财务官和首席会计官。在加入Radius之前，Dolan先生于2005年9月至2017年7月在Shire plc工作，在那里他担任越来越重要的财务管理职务，包括2016年5月至2017年7月担任财务副总裁，全球产品战略和高级财务总监，2013年5月至2016年5月，GI/内科。Dolan先生获得了Widener大学的工商管理硕士和工商管理硕士学位。
- Daniel Dolan has served as our chief financial officer since March 12 2021. Mr. Dolan previously served as Vice President of Finance at Radius Health, Inc., or Radius, a commercial-stage biopharmaceutical company, from July 2017 to January 2021. He also acted as principal financial officer and principal accounting officer of Radius from September 2020 to December 2020. Prior to joining Radius, Mr. Dolan worked at Shire plc from September 2005 to July 2017 where he held financial management positions of increasing responsibility, including Vice President of Finance, Global Product Strategy from May 2016 to July 2017 and Senior Finance Director, GI/Internal Medicine from May 2013 to May 2016. Mr. Dolan received his M.B.A. and B.S. from Widener University.